Shanghai TheraMabs Bio-technology co., LTD
We are professional supplier in antibodies and fusion proteins,such as Pembrolizumab, Nivolumab, Transtuzumab,etc.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
Purchase
Description
LUCENTIS® (ranibizumab) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.
Ranibizumab is supplied at a concentration of 10 mg/mL as a sterile, colorless to pale yellow solution, which contains 10 mM histidine HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.
Properties
Name | Ranibizumab |
CAS NO. | 347396-82-1 |
Type | Fab fragment |
Source | Humanized (from mouse) |
Target | VEGF-A |
Clone | Monoclone |
Molecular Weight | 48 kDa |
Formula | C2158H3282N562O681S12 |
Antibody Form | Purified immunoglobulin |
Physical Form | Solution |
Grade Standard | Medicine Grade |
Place of Origin | China(Mainland) |
Storage | -70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light. |
Supply Ability
20 kilogram per year, 1 Gram（Min. Order）.
Material Safety Data Sheet
If you need more information, please contact us.
Certificate Of Analysis
If you need more information, please contact us.
Detail information about the product please refer the website below:
https://en.wikipedia.org/wiki/Ranibizumab
